Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Herbal granules may offer new hope for aging kidneys

NCT ID NCT07741292

Disease control Sponsor: Huashan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study tests whether a traditional Chinese medicine, Niaoduqing granules, can slow the decline of kidney function in adults over 60 with chronic kidney disease. Participants will take the granules three times daily for a year while continuing their usual care. Researchers will track kidney function, nutrition, frailty, and other health outcomes to see if the treatment offers benefits. The study also looks at gut bacteria and blood markers to understand how the granules might work.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Niaoduqing Granules
What this could lead to
If effective, this treatment could slow the progression of chronic kidney disease in older adults, potentially delaying the need for dialysis and improving quality of life.
What could go wrong
This is a real-world study, not a controlled trial, so results may be influenced by other factors. The benefits are uncertain, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Nov 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

61 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants with stage 3 to 5 chronic kidney disease who are not receiving dialysis. 2. Age older than 60 years. 3. The participant or a family member has sufficient literacy and is able to comply with dietary diary recording and other study-related examinations. 4. The underlying cause of chronic kidney disease is clinically stable. Exclusion Criteria: 1. Malignancy, severe cardiovascular disease, osteoporosis, or severe hematopoietic system disease. 2. Active infection, defined as C-reactive protein greater than 10 mg/L, or current use of nephrotoxic medications. 3. Limb paralysis or major limb impairment. 4. Use of immunosuppressive therapy, including cyclosporine or tacrolimus, within the 3 months before cohort enrollment, or use of corticosteroids at a dose equivalent to more than 10 mg/day of prednisone. 5. Severe gastrointestinal disease affecting nutrient absorption. 6. Current participation in, or participation within the previous month in, another study related to diet or medication. 7. Known allergy to Niaoduqing Granules. 8. Any condition that, in the investigator's judgment, makes the participant unsuitable for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome Frailty Malnutrition

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Huashan Hospital, Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, 20040, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.